Markets & Regulations

Biopharma causes Cambrex bleed

Biopharma causes Cambrex bleed

By Gregory Roumeliotis

Life sciences firm Cambrex has reported a $140.3m (€116.7m) loss in
Q4 as opposed to a profit of $4.9m in Q4 last year, hit by lower
long-term profitability projections for its Biopharma unit, as
biotech companies seem to lose their...

Investors show faith in Biopure

Investors show faith in Biopure

By Gregory Roumeliotis

Oxygen therapeutics company Biopure has announced another $3
million (€2.5 million) public offering to boost its working
capital, despite its major drug for humans, Hemopure, an artificial
blood product, being licensed only in South...

Biogenerics debate rumbles on

Biogenerics debate rumbles on

Representatives of the pharmaceutical and biotechnology industries
presented strong opposition to the concept of biogenerics at a
recent meeting convened by the US Food and Drug Administration. As
expected, their argument centred...

Biopharma merger in UK

Biopharma merger in UK

Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.

Follow us